Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | POLB | P06746 | 4/20 | 0.65 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332891 | 0.89 | MAPT (0.67) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL13561219 | 0.88 | MEN1 (0.76) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL7304335 | 0.88 | HTT (0.72) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL2033537 | 0.85 | MEN1 (0.74) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL4254980 | 0.85 | TP53 (0.75) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL29961312 | 0.83 | HTT (0.82) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL14288427 | 0.82 | MEN1 (0.68) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL12359723 | 0.81 | HTT (0.78) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL2502044 | 0.81 | HTT (0.76) | MAPTMEN1KMT2APOLBKCNMA1 | |
| SCHEMBL8174145 | 0.80 | MEN1 (0.62) | MAPTMEN1KMT2APOLBKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2022159454-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | MAPT 2774/4885MEN1 1436/4885KMT2A 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.